Chronic antidepressant treatment effects on kinase gene expression patterns

J. L. Rausch, Y. Fei, M. E. Johnson, B. Jackson, V. Ganapathy, H. M. Hobby, F. H. Leibach

Research output: Contribution to journalArticle

Abstract

The serotonin transporter, SERT, is a phosphoprotein whose function is determined by its phosphorylation state via multiple kinase pathways. At least two fundamental phosphorylation mechanisms may regulate SERT activity. Phosphorylation through protein kinases may serve both to regulate sequestration of SERT from the cell membrane, and also down-regulate SERT expression. Ligand occupancy has been recently shown to affect this system, with SSRIs blocking 5-HT's ability to inhibit phosphorylation-mediated sequestration of SERT. Consequently, the kinases may serve to regulate extracellular 5-HT concentrations with SERT upregulation in response to increased 5-HT, and down regulation of SERT in response to SSRIs. If this were true, then we might expect to see differences in protein kinase expression in response to SSRI treatment. To investigate this possibility, we studied 5 groups of rats 5 rats in each group (N = 25, males). Rats were assigned randomly to osmotic mini-pump treatment with placebo 3 days, placebo 21 days, fluoxetine 3 days, fluoxetine 21 days, or citalopram 21 days. Total RNA was isolated and labeled as cRNA, and incubated with Affymetrix gene chip and stained with Streptavidin-phycoerythrin conjugate, and read for changes in the kinase expression system as a result of antidepressant treatment. The results indicated that expression of several protein kinases increased with acute and decreased with chronic antidepressant treatment. The results are consistent with homeostasis of SERT function through a decrease in PK manufacture, in response to antidepressant treatment. The results suggest that gene variation in this system may underlie differences in response to antidepressant treatment since kinase down-regulation would counterbalance the SSRI effect, by lessening inhibition of SERT function, in response to treatment.

Original languageEnglish (US)
Number of pages1
JournalAmerican Journal of Medical Genetics - Neuropsychiatric Genetics
Volume105
Issue number7
StatePublished - Oct 8 2001

Fingerprint

Antidepressive Agents
Phosphotransferases
Gene Expression
Phosphorylation
Protein Kinases
Serotonin
Down-Regulation
Fluoxetine
Therapeutics
Placebos
Phycoerythrin
Complementary RNA
Serotonin Plasma Membrane Transport Proteins
Citalopram
Streptavidin
Phosphoproteins
Oligonucleotide Array Sequence Analysis
Homeostasis
Up-Regulation
Cell Membrane

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Rausch, J. L., Fei, Y., Johnson, M. E., Jackson, B., Ganapathy, V., Hobby, H. M., & Leibach, F. H. (2001). Chronic antidepressant treatment effects on kinase gene expression patterns. American Journal of Medical Genetics - Neuropsychiatric Genetics, 105(7).

Chronic antidepressant treatment effects on kinase gene expression patterns. / Rausch, J. L.; Fei, Y.; Johnson, M. E.; Jackson, B.; Ganapathy, V.; Hobby, H. M.; Leibach, F. H.

In: American Journal of Medical Genetics - Neuropsychiatric Genetics, Vol. 105, No. 7, 08.10.2001.

Research output: Contribution to journalArticle

Rausch, JL, Fei, Y, Johnson, ME, Jackson, B, Ganapathy, V, Hobby, HM & Leibach, FH 2001, 'Chronic antidepressant treatment effects on kinase gene expression patterns', American Journal of Medical Genetics - Neuropsychiatric Genetics, vol. 105, no. 7.
Rausch, J. L. ; Fei, Y. ; Johnson, M. E. ; Jackson, B. ; Ganapathy, V. ; Hobby, H. M. ; Leibach, F. H. / Chronic antidepressant treatment effects on kinase gene expression patterns. In: American Journal of Medical Genetics - Neuropsychiatric Genetics. 2001 ; Vol. 105, No. 7.
@article{fde15639cd324fd8b3a771f74aa88af2,
title = "Chronic antidepressant treatment effects on kinase gene expression patterns",
abstract = "The serotonin transporter, SERT, is a phosphoprotein whose function is determined by its phosphorylation state via multiple kinase pathways. At least two fundamental phosphorylation mechanisms may regulate SERT activity. Phosphorylation through protein kinases may serve both to regulate sequestration of SERT from the cell membrane, and also down-regulate SERT expression. Ligand occupancy has been recently shown to affect this system, with SSRIs blocking 5-HT's ability to inhibit phosphorylation-mediated sequestration of SERT. Consequently, the kinases may serve to regulate extracellular 5-HT concentrations with SERT upregulation in response to increased 5-HT, and down regulation of SERT in response to SSRIs. If this were true, then we might expect to see differences in protein kinase expression in response to SSRI treatment. To investigate this possibility, we studied 5 groups of rats 5 rats in each group (N = 25, males). Rats were assigned randomly to osmotic mini-pump treatment with placebo 3 days, placebo 21 days, fluoxetine 3 days, fluoxetine 21 days, or citalopram 21 days. Total RNA was isolated and labeled as cRNA, and incubated with Affymetrix gene chip and stained with Streptavidin-phycoerythrin conjugate, and read for changes in the kinase expression system as a result of antidepressant treatment. The results indicated that expression of several protein kinases increased with acute and decreased with chronic antidepressant treatment. The results are consistent with homeostasis of SERT function through a decrease in PK manufacture, in response to antidepressant treatment. The results suggest that gene variation in this system may underlie differences in response to antidepressant treatment since kinase down-regulation would counterbalance the SSRI effect, by lessening inhibition of SERT function, in response to treatment.",
author = "Rausch, {J. L.} and Y. Fei and Johnson, {M. E.} and B. Jackson and V. Ganapathy and Hobby, {H. M.} and Leibach, {F. H.}",
year = "2001",
month = "10",
day = "8",
language = "English (US)",
volume = "105",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Chronic antidepressant treatment effects on kinase gene expression patterns

AU - Rausch, J. L.

AU - Fei, Y.

AU - Johnson, M. E.

AU - Jackson, B.

AU - Ganapathy, V.

AU - Hobby, H. M.

AU - Leibach, F. H.

PY - 2001/10/8

Y1 - 2001/10/8

N2 - The serotonin transporter, SERT, is a phosphoprotein whose function is determined by its phosphorylation state via multiple kinase pathways. At least two fundamental phosphorylation mechanisms may regulate SERT activity. Phosphorylation through protein kinases may serve both to regulate sequestration of SERT from the cell membrane, and also down-regulate SERT expression. Ligand occupancy has been recently shown to affect this system, with SSRIs blocking 5-HT's ability to inhibit phosphorylation-mediated sequestration of SERT. Consequently, the kinases may serve to regulate extracellular 5-HT concentrations with SERT upregulation in response to increased 5-HT, and down regulation of SERT in response to SSRIs. If this were true, then we might expect to see differences in protein kinase expression in response to SSRI treatment. To investigate this possibility, we studied 5 groups of rats 5 rats in each group (N = 25, males). Rats were assigned randomly to osmotic mini-pump treatment with placebo 3 days, placebo 21 days, fluoxetine 3 days, fluoxetine 21 days, or citalopram 21 days. Total RNA was isolated and labeled as cRNA, and incubated with Affymetrix gene chip and stained with Streptavidin-phycoerythrin conjugate, and read for changes in the kinase expression system as a result of antidepressant treatment. The results indicated that expression of several protein kinases increased with acute and decreased with chronic antidepressant treatment. The results are consistent with homeostasis of SERT function through a decrease in PK manufacture, in response to antidepressant treatment. The results suggest that gene variation in this system may underlie differences in response to antidepressant treatment since kinase down-regulation would counterbalance the SSRI effect, by lessening inhibition of SERT function, in response to treatment.

AB - The serotonin transporter, SERT, is a phosphoprotein whose function is determined by its phosphorylation state via multiple kinase pathways. At least two fundamental phosphorylation mechanisms may regulate SERT activity. Phosphorylation through protein kinases may serve both to regulate sequestration of SERT from the cell membrane, and also down-regulate SERT expression. Ligand occupancy has been recently shown to affect this system, with SSRIs blocking 5-HT's ability to inhibit phosphorylation-mediated sequestration of SERT. Consequently, the kinases may serve to regulate extracellular 5-HT concentrations with SERT upregulation in response to increased 5-HT, and down regulation of SERT in response to SSRIs. If this were true, then we might expect to see differences in protein kinase expression in response to SSRI treatment. To investigate this possibility, we studied 5 groups of rats 5 rats in each group (N = 25, males). Rats were assigned randomly to osmotic mini-pump treatment with placebo 3 days, placebo 21 days, fluoxetine 3 days, fluoxetine 21 days, or citalopram 21 days. Total RNA was isolated and labeled as cRNA, and incubated with Affymetrix gene chip and stained with Streptavidin-phycoerythrin conjugate, and read for changes in the kinase expression system as a result of antidepressant treatment. The results indicated that expression of several protein kinases increased with acute and decreased with chronic antidepressant treatment. The results are consistent with homeostasis of SERT function through a decrease in PK manufacture, in response to antidepressant treatment. The results suggest that gene variation in this system may underlie differences in response to antidepressant treatment since kinase down-regulation would counterbalance the SSRI effect, by lessening inhibition of SERT function, in response to treatment.

UR - http://www.scopus.com/inward/record.url?scp=33749114497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749114497&partnerID=8YFLogxK

M3 - Article

VL - 105

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 7

ER -